Pulike Biological Engineering, Inc. (SHA:603566)
China · Delayed Price · Currency is CNY 10.45
-0.10 (-0.95%)
Sep 2, 2026, 2:19 PM CST
SHA:603566 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,607 | 4,250 | 4,363 | 7,838 | 9,468 | 6,954 | |
Market Cap Growth | -28.62% | -2.59% | -44.34% | -17.21% | 36.16% | 6.31% |
Enterprise Value | 3,016 | 3,456 | 3,798 | 7,016 | 8,408 | 6,618 |
Last Close Price | 10.55 | 11.96 | 11.78 | 20.36 | 23.87 | 19.14 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 24.53 | 22.97 | 47.01 | 44.91 | 56.42 | 28.48 |
Forward PE | 21.10 | 20.38 | 19.73 | 27.90 | 35.98 | 21.72 |
PS Ratio | 3.53 | 3.90 | 4.18 | 6.26 | 7.70 | 6.33 |
PB Ratio | 1.35 | 1.55 | 1.66 | 2.88 | 3.38 | 3.86 |
P/TBV Ratio | 1.63 | 1.87 | 1.87 | 3.24 | 3.79 | 4.62 |
P/FCF Ratio | 20.52 | 15.11 | 29.53 | - | - | - |
P/OCF Ratio | 15.07 | 11.93 | 16.23 | 27.72 | 41.46 | 32.72 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.95 | 3.17 | 3.64 | 5.60 | 6.84 | 6.02 |
EV/EBITDA Ratio | 11.19 | 11.57 | 16.66 | 26.71 | 33.66 | 23.52 |
EV/EBIT Ratio | 23.17 | 19.34 | 35.44 | 41.06 | 47.81 | 29.80 |
EV/FCF Ratio | 17.16 | 12.29 | 25.71 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.01 | 0 | 0.00 | 0.00 | - |
Debt / EBITDA Ratio | 0.10 | 0.09 | 0.01 | 0.01 | 0.04 | - |
Debt / FCF Ratio | 0.15 | 0.10 | 0.01 | - | - | - |
Net Debt / Equity Ratio | -0.27 | -0.27 | -0.26 | -0.26 | -0.34 | -0.13 |
Net Debt / EBITDA Ratio | -2.66 | -2.50 | -3.00 | -2.75 | -3.86 | -0.87 |
Net Debt / FCF Ratio | -4.03 | -2.65 | -4.63 | 32.55 | 7.48 | 2.32 |
Asset Turnover | 0.33 | 0.34 | 0.33 | 0.38 | 0.44 | 0.52 |
Inventory Turnover | 1.99 | 2.12 | 2.16 | 2.60 | 2.54 | 2.50 |
Quick Ratio | 2.82 | 2.68 | 2.45 | 2.35 | 2.65 | 1.60 |
Current Ratio | 3.46 | 3.22 | 2.92 | 2.77 | 3.03 | 2.12 |
Return on Equity (ROE) | 5.04% | 6.90% | 3.47% | 6.31% | 7.29% | 13.91% |
Return on Assets (ROA) | 2.63% | 3.53% | 2.11% | 3.21% | 3.95% | 6.62% |
Return on Invested Capital (ROIC) | 5.76% | 8.11% | 5.11% | 7.98% | 9.78% | 13.89% |
Return on Capital Employed (ROCE) | 4.80% | 6.40% | 4.00% | 6.20% | 6.20% | 12.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.05% | 4.35% | 2.13% | 2.23% | 1.77% | 3.51% |
FCF Yield | 4.87% | 6.62% | 3.39% | -0.28% | -1.36% | -1.51% |
Dividend Yield | 5.76% | 5.02% | 3.40% | 3.44% | 1.47% | 1.04% |
Payout Ratio | 140.65% | 110.90% | 148.53% | 128.93% | 37.93% | 64.44% |
Buyback Yield / Dilution | -0.38% | 0.33% | 1.52% | -8.15% | -3.11% | 1.05% |
Total Shareholder Return | 5.38% | 5.35% | 4.92% | -4.71% | -1.64% | 2.09% |